Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taho PharmaceuticalsROCO:6467 -4.22%35 Piotroski F-Score is 6 as of Jul. 19, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates ROCO:6467 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 980 Drug Manufacturers companies, Taho Pharmaceuticals ranks better than 78.98% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Taho Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Taho Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
ROCO:6467'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 4 Max: 6
Current: 6
During the past 9 years, the highest Piotroski F-Score of Taho Pharmaceuticals was 6. The lowest was 3. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Taho Pharmaceuticals Piotroski F-Score Related Terms
Taho Pharmaceuticals Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Taho Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6467 vs ZTS, UTHR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Taho Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taho Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Taho Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Taho Pharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Taho Pharmaceuticals's current Net Income (TTM) was -214.40.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Taho Pharmaceuticals's current Cash Flow from Operations (TTM) was -203.73.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Taho Pharmaceuticals's return on assets of this year was -0.38237833. Taho Pharmaceuticals's return on assets of last year was -0.59124423.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Taho Pharmaceuticals's gearing of this year was 0.01134518. Taho Pharmaceuticals's gearing of last year was 0.02681149.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Taho Pharmaceuticals's current ratio of this year was 15.11496813. Taho Pharmaceuticals's current ratio of last year was 15.08997974.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Taho Pharmaceuticals's number of shares in issue this year was 51.477. Taho Pharmaceuticals's number of shares in issue last year was 45.396.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Taho Pharmaceuticals's gross margin of this year was 0.64292509. Taho Pharmaceuticals's gross margin of last year was .
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Taho Pharmaceuticals's asset turnover of this year was 0.01499922. Taho Pharmaceuticals's asset turnover of last year was 0.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
1
+
0
+
1
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Taho Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Taho Pharmaceuticals (ROCO:6467) has a Piotroski F-Score of 6 as of Jul. 19, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Taho Pharmaceuticals and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Taho Pharmaceuticals' Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, Taho Pharmaceuticals ranks #206 out of 980 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Taho Pharmaceuticals' Piotroski F-Score too high?
Taho Pharmaceuticals' current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Taho Pharmaceuticals' value of 6 is 20% above this industry median. Based on the distribution chart, Taho Pharmaceuticals ranks #206 out of 980 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Taho Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Taho Pharmaceuticals' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Taho Pharmaceuticals ranks #206 out of 980 companies for Piotroski F-Score. This places Taho Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Taho Pharmaceuticals' value of 6 is 20% above this benchmark. Historically, Taho Pharmaceuticals' own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Taho Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taho Pharmaceuticals's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Taho Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taho Pharmaceuticals's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taho Pharmaceuticals stock overvalued right now?
Taho Pharmaceuticals (ROCO:6467) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 20% above the Drug Manufacturers industry median of 5.00. Taho Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Taho Pharmaceuticals (ROCO:6467), the current Piotroski F-Score is 6 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
35GF Score
Get the complete analysis for ROCO:6467
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6467 has been successfully added to your 
